AFMD - Affimed stock jumps 22% after reporting 100% ORR in Phase 1-2 lymphoma study

Affimed (NASDAQ:AFMD) soars 21.6% premarket after announcing interim clinical results from Phase 1-2 study, evaluating cord blood-derived natural killer (cbNK) cells pre-complexed with Affimed’s innate cell engager (NYSE:ICE) AFM13. As of October 31, 2021, a total of 18 patients with CD30-positive relapsed or refractory Hodgkin and non-Hodgkin lymphomas (16 and 2 patients, respectively) were treated with the novel combination of cbNK cells pre-complexed with AFM13. As of the cutoff date, 16 of 18 patients had achieved an objective response to the treatment according to investigator assessment, with seven complete responses (CR) and nine partial responses. 100% objective response rate (ORR) was observed with a 42% CR rate in 12 patients with Hodgkin Lymphoma, after the 1st of 2 planned cycles at the recommended phase 2 dose of 108 cbNK cells/kg pre-complexed with AFM13. No cases of serious adverse events such as cytokine release syndrome, neurotoxicity syndrome or graft-versus-host disease were observed. Treatment was

For further details see:

Affimed stock jumps 22% after reporting 100% ORR in Phase 1-2 lymphoma study